China Shineway Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
China Shineway Pharmaceutical Group has been growing earnings at an average annual rate of 20.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 13.4% per year. China Shineway Pharmaceutical Group's return on equity is 15.1%, and it has net margins of 26.3%.
Key information
20.8%
Earnings growth rate
21.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 13.4% |
Return on equity | 15.1% |
Net Margin | 26.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How China Shineway Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 4,205 | 1,105 | 2,111 | 107 |
31 Mar 24 | 4,361 | 1,037 | 2,212 | 109 |
31 Dec 23 | 4,517 | 970 | 2,314 | 110 |
30 Sep 23 | 4,525 | 926 | 2,318 | 124 |
30 Jun 23 | 4,534 | 883 | 2,323 | 137 |
31 Mar 23 | 4,242 | 803 | 2,215 | 127 |
31 Dec 22 | 3,951 | 723 | 2,107 | 117 |
30 Sep 22 | 3,718 | 651 | 2,004 | 117 |
30 Jun 22 | 3,485 | 579 | 1,902 | 116 |
31 Mar 22 | 3,354 | 568 | 1,832 | 115 |
31 Dec 21 | 3,224 | 557 | 1,763 | 113 |
30 Sep 21 | 3,122 | 453 | 1,676 | 109 |
30 Jun 21 | 3,020 | 350 | 1,590 | 105 |
31 Mar 21 | 2,838 | 322 | 1,528 | 102 |
31 Dec 20 | 2,656 | 295 | 1,466 | 100 |
30 Sep 20 | 2,592 | 382 | 1,425 | 88 |
30 Jun 20 | 2,528 | 469 | 1,384 | 77 |
31 Mar 20 | 2,617 | 486 | 1,393 | 90 |
31 Dec 19 | 2,706 | 503 | 1,402 | 103 |
30 Sep 19 | 2,670 | 520 | 1,367 | 102 |
30 Jun 19 | 2,633 | 537 | 1,332 | 100 |
31 Mar 19 | 2,602 | 521 | 1,293 | 114 |
31 Dec 18 | 2,570 | 506 | 1,254 | 128 |
30 Sep 18 | 2,492 | 516 | 1,174 | 136 |
30 Jun 18 | 2,413 | 526 | 1,095 | 144 |
31 Mar 18 | 2,166 | 489 | 929 | 120 |
31 Dec 17 | 1,920 | 452 | 763 | 97 |
30 Sep 17 | 1,897 | 474 | 708 | 81 |
30 Jun 17 | 1,873 | 496 | 653 | 66 |
31 Mar 17 | 1,933 | 542 | 651 | 70 |
31 Dec 16 | 1,993 | 589 | 648 | 74 |
30 Sep 16 | 1,935 | 569 | 659 | 79 |
30 Jun 16 | 1,877 | 549 | 669 | 84 |
31 Mar 16 | 1,966 | 603 | 673 | 76 |
31 Dec 15 | 2,055 | 658 | 678 | 69 |
30 Sep 15 | 2,147 | 672 | 691 | 73 |
30 Jun 15 | 2,239 | 685 | 705 | 78 |
31 Mar 15 | 2,234 | 695 | 701 | 79 |
31 Dec 14 | 2,229 | 705 | 697 | 80 |
30 Sep 14 | 2,228 | 704 | 697 | 79 |
30 Jun 14 | 2,227 | 703 | 698 | 78 |
31 Mar 14 | 2,207 | 693 | 699 | 81 |
31 Dec 13 | 2,187 | 684 | 701 | 83 |
Quality Earnings: CSWY.Y has high quality earnings.
Growing Profit Margin: CSWY.Y's current net profit margins (26.3%) are higher than last year (19.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSWY.Y's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: CSWY.Y's earnings growth over the past year (25.1%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: CSWY.Y earnings growth over the past year (25.1%) did not outperform the Pharmaceuticals industry 54.6%.
Return on Equity
High ROE: CSWY.Y's Return on Equity (15.1%) is considered low.